Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dopamine therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    117 result(s) found for: Dopamine therapy. Displaying page 6 of 6.
    « Previous 1  2  3  4  5  6 
    EudraCT Number: 2007-002823-34 Sponsor Protocol Number: 27818 Start Date*: 2007-11-08
    Sponsor Name:Merck Serono International S.A
    Full Title: A phase II, multicentre, randomised, assessor.blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f) in oligo-anovulatory infe...
    Medical condition: oligoanovulatory infertile women who are candidates for ovulation induction (OI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033312 Ovulation induction PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) ES (Completed) DK (Completed) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004752-16 Sponsor Protocol Number: BP40283 Start Date*: 2021-07-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF RO6889450 (RALMITARONT) IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AND NEGATIVE SYMPTOMS
    Medical condition: Schizophrenia or schizoaffective disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002994-39 Sponsor Protocol Number: Cx611-0204 Start Date*: 2016-04-06
    Sponsor Name:TIGENIX, S.A.U.
    Full Title: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for...
    Medical condition: Severe community-acquired bacterial pneumonia requiring mechanical ventilation and/or vasopressors.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) LT (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004460-39 Sponsor Protocol Number: 248.644 Start Date*: 2008-11-11
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age...
    Medical condition: Tourette's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10044127 Tourette's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006075-20 Sponsor Protocol Number: 06-009 Start Date*: 2007-08-20
    Sponsor Name:Jazz Pharmaceuticals, Inc.
    Full Title: Estudio aleatorizado, doble ciego, controlado con placebo, de la seguridad y eficacia de Xyrem® (oxibato sódico) en sujetos con fibromialgia (A Randomized, Double-Blind, Placebo-Controlled, Safety...
    Medical condition: fibromialgia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10048439 Fibromyalgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) NL (Completed) PL (Completed) GB (Completed) IT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005626-19 Sponsor Protocol Number: CVT-301-004E Start Date*: 2016-06-23
    Sponsor Name:Civitas Therapeutics, Inc.
    Full Title: A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
    Medical condition: Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10034007 Parkinson's disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-003732-30 Sponsor Protocol Number: NbT 01-06 / TULEP 1 Start Date*: 2007-01-31
    Sponsor Name:Axxonis Pharma AG
    Full Title: Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS
    Medical condition: Early Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000246-19 Sponsor Protocol Number: 3-3002 Start Date*: 2018-09-24
    Sponsor Name:Asahi Kasei Pharma America Corporation
    Full Title: SCARLET-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Sepsis and Coagulopathy
    Medical condition: Sepsis, defined by the presence of infection and host inflammation, is a lethal clinical syndrome. In severe disease, the coagulation system becomes diffusely activated, with consumption of multipl...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10053840 Bacterial sepsis PT
    20.0 10005329 - Blood and lymphatic system disorders 10009802 Coagulopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001786-10 Sponsor Protocol Number: EPI589-15-002 Start Date*: 2016-01-18
    Sponsor Name:BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
    Full Title: A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson’s Disease Subjects
    Medical condition: Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023986-23 Sponsor Protocol Number: LF-0802 Start Date*: 2011-05-27
    Sponsor Name:Agennix Incorporated
    Full Title: OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis
    Medical condition: Severe Sepsis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10040047 Sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002254-70 Sponsor Protocol Number: 6002-014 Start Date*: 2014-02-28
    Sponsor Name:Kyowa Kirin Pharmaceutical Development, Inc.
    Full Title: A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Sever...
    Medical condition: Moderate to severe Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    19.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005495-19 Sponsor Protocol Number: RVT-101-2001 Start Date*: 2016-06-13
    Sponsor Name:Axovant Sciences Inc.
    Full Title: A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB).
    Medical condition: Dementia with Lewy Bodies
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002448-10 Sponsor Protocol Number: BIA-51058-201 Start Date*: 2018-10-31
    Sponsor Name:Bial - Portela & Ca, S.A.
    Full Title: An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)
    Medical condition: Pulmonary arterial hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) PT (Completed) ES (Ongoing) GB (Temporarily Halted) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002133-37 Sponsor Protocol Number: COR-2012-01 Start Date*: 2014-11-17
    Sponsor Name:Cortendo AB
    Full Title: An Open Label Study to Assess the Safety and Efficacy of COR—003 (2S, 4R-Ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing's syndrome (CS) or Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) BE (Completed) NL (Completed) SE (Completed) DK (Completed) DE (Completed) IT (Completed) BG (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-002193-31 Sponsor Protocol Number: CRN00808-05 Start Date*: 2020-02-19
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRN00808 IN SUBJECTS WITH ACROMEGALY (ACROBAT ADVANCE)
    Medical condition: Acromegaly is typically caused by a growth hormone (GH) secreting tumor in the pituitary. Excess GH secretion results in excess secretion of insulin-like growth factor-1 (IGF-1) from the liver, whi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SK (Completed) GR (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015161-31 Sponsor Protocol Number: P04938 Start Date*: 2010-08-17
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) CZ (Completed) FR (Completed) NL (Completed) ES (Completed) AT (Completed) DE (Completed) IT (Completed) SE (Completed) PT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000185-12 Sponsor Protocol Number: CELC200A2401 / 2939107 Start Date*: 2004-09-21
    Sponsor Name:Orion Corporation, ORION PHARMA
    Full Title: A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061536 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 16:41:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA